We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Test May Identify Higher Risk Pregnancies in Women Diagnosed with COVID-19

By LabMedica International staff writers
Posted on 18 Mar 2022
Print article
Image: A new blood test could improve COVID-19 care in pregnancies (Photo courtesy of Northwestern University)
Image: A new blood test could improve COVID-19 care in pregnancies (Photo courtesy of Northwestern University)

Research has shown pregnant people with COVID-19 have a higher risk of stillbirths and other pregnancy complications. Anecdotal reports have reported potentially higher cases of stillbirths caused by certain SARS-CoV-2 variants, leading to increased concern in the scientific community. Scientists had identified a link between COVID placentitis, in which the virus infects the placenta, and these poor outcomes, but can only diagnose instances of placentitis after delivery by examining the placenta. A new study has now shown that a blood test may identify risk of stillbirth and placentitis in pregnant individuals who have had COVID-19.

The finding of the small preliminary study by researchers at Northwestern University (Evanston, IL, USA) builds on another study with similar results and could have implications in how physicians screen for and address high-risk pregnancies. The new study illuminates a link between placentitis and circulating SARS-CoV-2 virus. Placentitis affects between 1% and 2% of pregnant people infected with COVID-19. Unlike many pregnancy complications, the risk of placentitis and stillbirth is not linked to the severity of the virus. According to the researchers, predicting which placentas are at risk next to impossible, because an asymptomatic infection could just as easily have complications as a very sick person.

Using a biorepository of blood taken from pregnant people during the pandemic in 2020, the scientists looked at the blood of participants who had tested positive for COVID-19 during pregnancy - six who were positive for placentitis and 12 controls who were not. Then, the scientists looked for RNA of the virus in maternal blood using the same PCR-based test usually performed on nasal swabs. Out of those who had placentitis, two had low levels of viral RNA (called viremia) in their blood; none of the controls did. One of the people with viremia had a stillbirth, and the other had a well infant; all participants who tested negative for the marker delivered healthy babies.

Most pregnant patients with COVID-19 will go on to have normal pregnancies. Improved versions of this test and additional studies to validate the finding could help obstetricians develop plans for those who are at a high risk of placentitis and stillbirth, according to the researchers. They plan to conduct follow-up studies with larger pools of participants and hope other labs will build on the small body of literature to further validate the findings. The best way to protect both the parent and baby is to get vaccinated, the researchers said. In their observations, stillbirths have been more common in unvaccinated patients.

“Right now, we don’t know if there’s placentitis until after the fact,” said Northwestern’s Dr. Leena Mithal, the study’s first author. “We’re laying groundwork for further studies so that in the future, people who are diagnosed with COVID during pregnancy may be able to get a test that will help identify pregnancies that may be at higher risk of stillbirth or fetal distress.”

“The part of the placenta infected by the virus is also the part that’s in contact with maternal blood,” said Dr. Elisheva Shanes, a co-investigator of the study. “So if there’s infection in these cells, the virus may also be found in the blood. If a pregnant person had COVID and no placentitis, we wouldn’t expect to find virus in the blood.”

Related Links:
Northwestern University 

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.